{"id":"W2897175439","doi":"10.1007/s00280-018-3689-2","title":"Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Rash; Trastuzumab; Diarrhea; Metastatic breast cancer; Cancer; Adverse effect; Oncology; Gastroenterology; Breast cancer; Surgery; Epidermal growth factor receptor; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001892474,0.001580089,0.002260442,0.00040291,0.0005268518,0.001129167,0.001185405,0.001714504,0.002833534],"category_scores_gemma":[0.001392464,0.0007147317,0.001588889,0.000521111,0.001142874,0.000939708,0.0004176871,0.003739554,0.0007239611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536161,"about_ca_system_score_gemma":0.00250645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001289384,"about_ca_topic_score_gemma":0.003161673,"domain_scores_codex":[0.9994742,0.000226953,0.00003409365,0.00009238001,0.00004867272,0.0001237126],"domain_scores_gemma":[0.9989448,0.000139493,0.000199222,0.00008214446,0.000061734,0.0005726331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8155054,0.06587776,0.004652675,0.0007598073,0.001683054,0.000330509,0.0003785662,0.003502302,0.02596833,0.0003689947,0.004860261,0.07611228],"study_design_scores_gemma":[0.7824784,0.2097065,0.004441073,0.00002107183,0.0001715805,0.0001977026,0.00002289595,0.0008096271,0.0009822791,0.0001447335,0.001004003,0.00002008718],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917901,0.002012651,0.000503612,0.0007960611,0.0001913469,0.002556308,0.000597839,0.00008518453,0.001466985],"genre_scores_gemma":[0.9898843,0.001122219,0.001906835,0.001123575,0.0001816884,0.002754645,0.001401836,0.00002789807,0.001596897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002833534,"threshold_uncertainty_score":0.01114565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02844610610364096,"score_gpt":0.4090134797091505,"score_spread":0.3805673736055095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}